Cardiovascular adverse events associated with EGFR and HER2 dual TKIs: a pharmacovigilance study based on the FAERS database
Disproportionality analysis results revealed a positive signal for cardiac failure, embolic and thrombotic events, and cardiomyopathy of lapatinib, and no positive signal for neratinib. We should pay attention to high-risk signals in clinical practice and monitor them appropriately.
Authors
- Henan Qin (ORCID: https://orcid.org/0000-0003-2989-7424)
- Yibin Teng
- Zhen Ning (ORCID: https://orcid.org/0000-0002-2901-2991)
- Jiwei Liu (ORCID: https://orcid.org/0000-0001-5040-6242)
- Peiyao Yu
Institutions
- Dalian Medical University (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1080/14740338.2025.2489529
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China